These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37296936)

  • 1. Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.
    Merola E; Grana CM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.
    Ambrosini V; Zanoni L; Filice A; Lamberti G; Argalia G; Fortunati E; Campana D; Versari A; Fanti S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Therapy.
    Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies.
    Ahmadi Bidakhvidi N; Goffin K; Dekervel J; Baete K; Nackaerts K; Clement P; Van Cutsem E; Verslype C; Deroose CM
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
    Harris PE; Zhernosekov K
    Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
    Shi M; Jakobsson V; Greifenstein L; Khong PL; Chen X; Baum RP; Zhang J
    Front Med (Lausanne); 2022; 9():1034315. PubMed ID: 36569154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
    Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
    Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radiotherapy Comes of Age.
    Al-Toubah T; Strosberg J
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):615-625. PubMed ID: 30098719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
    Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
    Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
    Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
    Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Rubira L; Deshayes E; Santoro L; Kotzki PO; Fersing C
    Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
    Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.